AU2020355253A1 - Heterodimeric proteins - Google Patents

Heterodimeric proteins Download PDF

Info

Publication number
AU2020355253A1
AU2020355253A1 AU2020355253A AU2020355253A AU2020355253A1 AU 2020355253 A1 AU2020355253 A1 AU 2020355253A1 AU 2020355253 A AU2020355253 A AU 2020355253A AU 2020355253 A AU2020355253 A AU 2020355253A AU 2020355253 A1 AU2020355253 A1 AU 2020355253A1
Authority
AU
Australia
Prior art keywords
amino acid
heterodimeric protein
seq
acid sequence
polypeptide comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020355253A
Other languages
English (en)
Inventor
Dhan Sidhartha CHAND
Veronica Franciszka ILKOW
Zahra JAWAD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agenus Inc
Original Assignee
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc filed Critical Agenus Inc
Publication of AU2020355253A1 publication Critical patent/AU2020355253A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020355253A 2019-09-27 2020-09-28 Heterodimeric proteins Abandoned AU2020355253A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962906918P 2019-09-27 2019-09-27
US62/906,918 2019-09-27
PCT/US2020/053114 WO2021062382A1 (en) 2019-09-27 2020-09-28 Heterodimeric proteins

Publications (1)

Publication Number Publication Date
AU2020355253A1 true AU2020355253A1 (en) 2022-03-24

Family

ID=75166489

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020355253A Abandoned AU2020355253A1 (en) 2019-09-27 2020-09-28 Heterodimeric proteins

Country Status (10)

Country Link
US (2) US20210130495A1 (https=)
EP (1) EP4034570A4 (https=)
JP (1) JP7842011B2 (https=)
KR (1) KR20220069935A (https=)
CN (1) CN114787186B (https=)
AU (1) AU2020355253A1 (https=)
BR (1) BR112022004789A2 (https=)
IL (1) IL291618A (https=)
MX (1) MX2022003149A (https=)
WO (1) WO2021062382A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3428194T (lt) 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE299938T1 (de) * 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005047327A2 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US10689447B2 (en) * 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CA2843158A1 (en) * 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
BR112014010580B1 (pt) * 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
ES2876009T3 (es) * 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
MY203000A (en) * 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins
KR20200014379A (ko) * 2017-06-05 2020-02-10 얀센 바이오테크 인코포레이티드 비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질
CN110028584B (zh) * 2018-01-12 2021-04-06 北京科昕生物科技有限公司 针对egfr蛋白和met蛋白的双特异性抗体
SG11202104136YA (en) * 2018-10-23 2021-05-28 Dragonfly Therapeutics Inc Heterodimeric fc-fused proteins

Also Published As

Publication number Publication date
WO2021062382A1 (en) 2021-04-01
CA3151574A1 (en) 2021-04-01
JP2022549351A (ja) 2022-11-24
US20240360249A1 (en) 2024-10-31
MX2022003149A (es) 2022-04-06
EP4034570A4 (en) 2023-10-25
CN114787186B (zh) 2025-06-03
CN114787186A (zh) 2022-07-22
KR20220069935A (ko) 2022-05-27
JP7842011B2 (ja) 2026-04-07
EP4034570A1 (en) 2022-08-03
US20210130495A1 (en) 2021-05-06
IL291618A (en) 2022-05-01
BR112022004789A2 (pt) 2022-06-21

Similar Documents

Publication Publication Date Title
JP7651031B2 (ja) Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
CA2797981C (en) Heterodimeric proteins and methods for producing and purifying them
US20240360249A1 (en) Heterodimeric proteins
KR20240093883A (ko) 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도
CA3151574C (en) Heterodimeric proteins
HK40077576A (zh) 异二聚体蛋白
CN117597365A (zh) 多特异性fgf21受体激动剂及其应用
HK40077576B (zh) 异二聚体蛋白
WO2021091906A1 (en) Methods for treating leukemia
CN118284625A (zh) 抗tyrp1/抗cd3双特异性抗体与tyrp1特异性抗体的组合疗法
EP4724477A1 (en) Circularized antibody molecules
WO2025090570A1 (en) Anti-ox40l antibodies and methods of use
AU2024369195A1 (en) Anti-ox40l antibodies and methods of use
HK40112962A (zh) 抗tyrp1/抗cd3双特异性抗体与tyrp1特异性抗体的组合疗法
TWI599577B (zh) Methods to alter the isoelectric point of antibodies using amino acid substitutions of CDR regions
HK1232553A (en) Method of modifying isoelectric point of antibody via amino acid substitution in cdr
HK1232553A1 (en) Method of modifying isoelectric point of antibody via amino acid substitution in cdr
HK1150363B (zh) 利用cdr的氨基酸取代来改变抗体等电点的方法
HK1150363A (en) Method of modifying isoelectric point of antibody via amino acid substitution in cdr

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application